Open Your FREE Demat Account Now!

Tejnaksh Healthcare Ltd. Share Price

NSE
BSE

BSE : 539428

Sector : Healthcare

N/A
indicator
1D
1M
3M
6M
1Y
5Y
empty graph

Day's Range

Low

₹

High

₹

Price Summary

Previous Close ₹15.50
Day's Range ₹15.32 - ₹16.55
Open ₹16.55
52 Week Range ₹10.65 - ₹18.54
Volume 3,568
Market Cap ₹0.00

Stocks Summary

Trade Value ( ₹ in Lacs) 0.55
Market Cap (₹ in Mn) 0.00
Dividend Yield(%) 0.00
Price/Earning (TTM) 20.57
TTM EPS (₹) 0.74
P/E Ratio 19.73
Book Value(₹) 1.11
PAT Margin (%) 10.95
Face Value (₹) 5.00
ROCE(%) 6.50

Financials

Particulars QTR FY (₹ in Millions) Annual FY (₹ in Millions)
Net sales 19.35 128.97
Expenses N/A N/A
PBT 4.23 31.91
Operating profit 0.0 0.0
Net profit 3.1 22.31

Shareholding Pattern

Promoters (% Holding)

73.83%

Mutual funds (% Holding)

0.00%

Non-Institution (% Holding)

26.17%

FI/Banks/Insurance (% Holding)

0.00%

Government (% Holding)

0.00%

FII

0.00%

About Tejnaksh Healthcare Ltd.

Founded 2008
Managing Director Ashish Vishwas Rawandale

Peer Comparision

Stocks Name Market Cap (Cr)(₹) Market Price (₹) 52 Week Low-High (₹)
Sun Pharmaceutical Industries Ltd. 4,56,593.44 1,885.00 1,583.70 - 1,583.70
Divi's Laboratories Ltd. 2,96,740.78 11,100.00 5,647.50 - 5,647.50
Torrent Pharmaceuticals Ltd. 1,75,577.80 4,667.20 3,672.30 - 3,672.30
Lenskart Solutions Ltd. 1,28,977.63 743.40 0.00 - 0.00
Apollo Hospitals Enterprise Ltd. 1,25,736.81 9,211.15 6,696.50 - 6,696.50
Laurus Labs Ltd. 1,24,379.87 2,307.35 917.95 - 917.95
Zydus Lifesciences Ltd. 1,19,700.46 1,198.95 835.50 - 835.50
Dr. Reddy's Laboratories Ltd. 1,16,770.96 1,392.40 1,101.00 - 1,101.00
Cipla Ltd. 1,14,396.95 1,414.20 1,165.70 - 1,165.70
Mankind Pharma Ltd. 1,08,640.97 2,651.40 1,909.70 - 1,909.70
no-content No Records Found

Latest News

Nov
2
2026
EQUITY Posted on Nov 2nd 2026

Tejnaksh Healthcare informs about disclosure

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Tejnaksh Healthcare has informed that, Dr. Ashish V. Rawandale-Patil, Managing Director of the company, has been selected as a Mentor for the Technology Innovation Program 2027 (ES-TIP 2027) of the Endourological Society, a globally recognized international organization in the field of urology. The Technology Innovation Program aims to support and mentor medical innovations and assist healthcare professionals in developing novel ideas for improving patient care, with promising innovations being considered for further development and commercialization. Dr.Ashish Rawandale-Patil has been selected as one of the mentors for the program and is the only urologist from outside the United States to join three other distinguished mentors from leading institutions in the United States. This recognition reflects his contribution to medical innovation and highlights India's growing presence on the global healthcare innovation platform. The Company believes that this prestigious international recognition enhances the reputation and visibility of Tejnaksh Healthcare and showcases the global expertise and leadership associated with the Company. 

The above information is a part of company’s filings submitted to BSE.
Read More
Nov
20
2026
EQUITY Posted on Nov 20th 2026

Lotus Eye Hospital and Institute informs about newspaper advertisements

Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, Lotus Eye Hospital and Institute has informed that it enclosed copies of the Newspaper Advertisements published today in Business Standard (English) and The Tamil Hindu (Tamil) regarding the Notice of Postal Ballot of the Company.
The above information is a part of company’s filings submitted to BSE.
Read More
Nov
20
2026
EQUITY Posted on Nov 20th 2026

NATCO Pharma informs about press release

NATCO Pharma has informed that it enclosed the Press Release under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 regarding the receipt of Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (FDA) Inspection at our Visakhapatnam, Andhra Pradesh, Finished Dosage Formulations (FDF) Unit.

The above information is a part of company’s filings submitted to BSE.
Read More
Nov
20
2026
EQUITY Posted on Nov 20th 2026

Wanbury informs about press release

Pursuant to Regulation 30 of SEBI LODR, Wanbury has informed that company’s API manufacturing facility at Tanuku, Andhra Pradesh, has successfully completed a three-day cGMP inspection conducted by the Ministry of Food and Drug Safety (MFDS), Republic of Korea, with zero observations. The inspection was conducted by two senior inspectors from South Korea’s MFDS, a leading international pharmaceutical regulatory authority, covering the facility’s compliance with applicable Good Manufacturing Practices (cGMP) standards. This achievement follows the successful completion of a South Korea MFDS cGMP inspection at the Company’s Patalganga manufacturing facility in April 2026, which was also concluded with zero observations. These consecutive achievements reflect Wanbury Limited’s strong commitment to quality, regulatory compliance and operational excellence. The Company remains focused on continuously strengthening its quality systems and enhancing manufacturing standards in line with evolving international regulatory requirements and global cGMP expectations. 

The above information is a part of company’s filings submitted to BSE.

Read More
Nov
19
2026
EQUITY Posted on Nov 19th 2026

Advanced Enzyme Technologies informs about updates on acquisition

With reference to intimation dated August 08, 2026, Advanced Enzyme Technologies has informed that the Company has completed the acquisition of additional stake of 1.22% in JC Biotech Private Limited, subsidiary [JCB] by way of purchase of 2,53,297 Equity Shares from few selling shareholders of JCB, for a consideration of ₹ 22.80 million i.e. ₹ 90 per Equity Share. In view of this, the shareholding of the Company in JCB has increased from 95.72% to 96.94% of paid-up share capital of JCB effective from November 18, 2026. Further, the Company is in the process of acquiring the remaining 3.06% equity stake in JCB. Upon completion of the said acquisition, JCB will become a Wholly Owned Subsidiary of the Company.
The above information is a part of company’s filings submitted to BSE.
Read More
no-content No Records Found

Sign in to Unlock Offers!

Explore Loans, Cards, Investments & Insurance

No SPAM We don't SPAM
Right Hand Side Image
STEP 1/2

Open Demat Account today!

+91

Enter mobile number

Invalid mobile number

Enter Full Name

Invalid Full Name

Verification required
close

Enter the One Time Password (OTP)

Sent to ********99

Edit Number
Enter valid OTP
Field should not be blank
You have exhausted your OTP attempts try again after 10 min

Request another in 60s

Resend OTP

secure   100% safe and secure

Frequently Asked Questions

What is the current share price of Tejnaksh Healthcare Ltd. ?

The current share price of Tejnaksh Healthcare Ltd. is ₹15.50 as of 2026-11-20.

The market capitalisation of Tejnaksh Healthcare Ltd. is ₹30.98 as of 2026-11-19.

The 1-year return of Tejnaksh Healthcare Ltd. is -0.95% as of 2025-11-19.

The P/E ratio of Tejnaksh Healthcare Ltd. is 19.73 as of 2026-11-20.

The 52-week high and low of Tejnaksh Healthcare Ltd. are ₹18.54 and ₹10.65, respectively, as of 2026-11-20.

The dividend yield of Tejnaksh Healthcare Ltd. is 0.0% as of2026-11-19.

You can buy Tejnaksh Healthcare Ltd. shares through a registered stockbroker or trading platform. Bajaj Markets partners with trusted brokers to help you open a demat account. This is the first step to trading, making it easier to invest in your desired shares.

The Managing Director of Tejnaksh Healthcare Ltd. is Ashish Vishwas Rawandale.

When investing in a company’s stock, you may consider key factors such as its fundamentals, including financial health, historical performance, and growth potential. Assess the consistency of its performance, market conditions, and industry trends. Additionally, evaluate your own risk tolerance while reviewing aspects like quarterly earnings, management quality, and sector performance, for taking a well-informed decision.

You can track stock performance on online platforms through live market updates, historical charts, and news alerts. Regular analysis and stock alerts allow you to stay informed about significant price changes and events affecting the stock.

Common stock provides voting rights and the potential for dividends based on company performance, while in case of preferred stock, stockholders receive fixed dividends and have priority over common stockholders in asset distribution but generally lack voting rights.

Stock investments carry market risks, including price volatility, economic shifts, and sector-specific issues. Managing risk can involve diversifying your portfolio, setting stop-loss orders, and staying informed about market trends to make timely decisions.

Market capitalisation, or market cap, is the total value of a company’s outstanding shares and is calculated by multiplying the stock price by the total shares. It classifies companies as large-cap, mid-cap, or small-cap, reflecting their size, stability, and potential risk level in the stock market.

View More

Disclaimer

All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.

The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.

Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform. 

Invalid Mobile Number

Invalid Full Name

Home
Home
ONDC_Shopping
Shopping
Loan
Loan Offers
My Accounts
My Accounts
Explore
Explore